Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project.
Peters, S Bubendorf, L Dafni, U Kerr, K Hager, H Soltermann, A O'Byrne, K Dooms, C Sejda, A
Peters, S
Bubendorf, L
Dafni, U
Kerr, K
Hager, H
Soltermann, A
O'Byrne, K
Dooms, C
Sejda, A
Citations
Altmetric:
Abstract
The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population.
Description
Date
2014-07-28
Publisher
Collections
Keywords
Type
Article
Citation
Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. 2014: J Clin Oncol